MGluR4 positive allosteric modulators with potential for the treatment of Parkinson's disease: WO09010455

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 3, 2010, Pages 441-445

  East, Stephen P ^a   Gerlach, Kai ^a,b  

^a EVOTEC UK LTD   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Addex; Allosteric modulators; MGluR4; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR ANTAGONIST; PYRAZOLE DERIVATIVE; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; WO 09010455;

ALLOSTERISM; BINDING SITE; BIOCHEMISTRY; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CLINICAL EVALUATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENCY; DYSKINESIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PARKINSON DISEASE; PATENT; RING OPENING; SHORT SURVEY; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION;

ALLOSTERIC REGULATION; ANIMALS; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; PARKINSON DISEASE; PATENTS AS TOPIC; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 77649149189     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903551295     Document Type: Short Survey

References (20)

1. Iverson SD, Iversen LL. Dopamine: 50 years in perspective. Trends Neurosci 2007;30:188-193
2. Lavreysen H, Dautzenberg FM. Therapeutic potential of group III metabotropic glutamate receptors. Curr Med Chem 2008;15:671-684
3. Conn PJ, Battaglia G, Marino MJ, Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005;6:787-798
4. Beurrier C, Lopez S, Revy D, et al. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB 2009;23:3619-3628
5. Marino MJ, Williams DL, Jr, O'Brien JA, et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci USA 2003;100:13668-13673
6. Battaglia G, Busceti CL, Molinaro G, et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine. J Neurosci 2006;26:7222-7229
7. Hopkins CR, Lindsley CW, Niswender CM. mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease. Future Med Chem 2009;1:501-513
8. Conn PJ, Christopoulos A, Lindsley, CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Disc 2009;8:41-54
9. Addex Partner Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator. Available from: http://www. addexpharma.com/press- releases/ press-release-details/article/ addex-partner-starts-first- everclinical- trial-of-an-mglur-positiveallosteric- modulator/
10. Niswender CM, Johnson KA, Weaver CD, et al. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol 2008;74:1345-1358
11. Williams RW, Johnson KA, Gentry PR, et al. Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4). Bioorg Med Chem Lett 2009;19:4967-4970
12. Niswender CM, Lebois EP, Luo Q, et al. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): part I. discovery of pyrazolo [3,4-d]pyrimidines as novel mGluR4 positive allosteric modulators. Bioorg Med Chem Lett 2008;18:5626-5630
13. Williams R, Niswender CM, Luo Q, et al. Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: challenges in hit-to-lead. Bioorg Med Chem Lett 2009;19:962-966
14. Addex Pharma S.A. Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO2009010454; 2009
15. Engers DW, Niswender CM, Weaver CD, et al. Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J Med Chem 2009;52:4115-4118
16. Lindsley CW, Niswender CM, Engers DW, Hopkins CR. Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease. Curr Top Med Chem 2009;9:949-963
17. Addex Pharma S.A. Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. WO2009010455; 2009
18. Sharma S, Kedrowski J, Rook JM, et al. Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl) pyrimidines. J Med Chem 2009;52:4103-4106
19. Addex Achieves Second Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc. Available from: http://www.addexpharma.com/ press-releases/press-release-details/article/ addex-achieves-second-milestonein- parkinsons-disease-collaborationwith- merck-co-inc/
20. Addex Extends Parkinson's Disease Collaboration with Merck & Co., Inc. Available from: http://www.addexpharma. com/press-releases/press-release- details/ article/addex-extends-parkinsons-diseasecollaboration- with-merck-co-inc/